| Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia (NCT05281809) | John Lister | 2022-04-19 |
| Monitoring Minimal Residual Disease（MRD）in Pediatric B-acute Lymphoblastic Leukemia (NCT04977895) | Sun Yat-sen University | 2021-01-30 |
| TT52CAR19 Therapy for B-cell Acute Lymphoblastic Leukaemia (B-ALL) (NCT04557436) | Great Ormond Street Hospital for Children NHS Foundation Trust | 2020-08-12 |
| Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy (NCT03959085) | Children's Oncology Group | 2019-10-31 |
| Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Leukemia or Lymphoma Undergoing Stem Cell Transplantation (NCT03856216) | M.D. Anderson Cancer Center | 2019-10-28 |
| A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia (NCT03914625) | National Cancer Institute (NCI) | 2019-07-03 |
| Combination Chemotherapy and Inotuzumab Ozogamicin in Treating Patients With B Acute Lymphoblastic Leukemia (NCT03488225) | M.D. Anderson Cancer Center | 2018-03-28 |
| Inotuzumab Ozogamicin in Treating Patients With B-cell Acute Lymphocytic Leukemia With Positive Minimal Residual Disease (NCT03441061) | M.D. Anderson Cancer Center | 2018-02-15 |
| The Clinical Application of Chimeric Antigen Receptor T Cells in the Treatment of CD19 Positive Recurrent Refractory B Cell-derived Hematological Malignancies (NCT04184414) | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | 2018-01-09 |
| Study of CD19/CD22 Chimeric Antigen Receptor T Cells in Children & Young Adults w/ Recurrent or Refractory B Cell Malignancies (NCT03241940) | Stanford University | 2017-10-20 |
| Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia (NCT03150693) | Alliance for Clinical Trials in Oncology | 2017-09-20 |
| CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells With or Without NKTR-255 in Adults With Recurrent or Refractory B Cell Malignancies (NCT03233854) | Stanford University | 2017-09-01 |
| Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (NCT03007147) | Children's Oncology Group | 2017-08-08 |
| CD19 /22 CAR T Cells (AUTO3) for the Treatment of B Cell Acute Lymphoblastic Leukemia (ALL) (NCT03289455) | Autolus Limited | 2017-06-26 |
| Sapanisertib in Treating Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia (NCT02484430) | National Cancer Institute (NCI) | 2017-04-06 |
| Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement (NCT02828358) | National Cancer Institute (NCI) | 2017-04-01 |
| Pembrolizumab in Treating Minimal Residual Disease in Patients With Acute Lymphoblastic Leukemia (NCT02767934) | University of Washington | 2017-01-13 |
| Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia (NCT02877303) | M.D. Anderson Cancer Center | 2016-11-01 |
| Identification of New Immune Factors Specific of Relapse in Childhood B Lineage Acute Lymphoblastic Leukemia (NCT02618109) | University Hospital, Angers | 2016-01-01 |
| Blinatumomab in Treating Patients With B-cell Acute Lymphoblastic Leukemia With Minimal Residual Disease (NCT02458014) | M.D. Anderson Cancer Center | 2015-09-14 |
| Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia (NCT02143414) | National Cancer Institute (NCI) | 2015-06-30 |
| A Phase I Trial of 4SCAR19 Cells in the Treatment of Relapsed and Refractory B Cell Leukemia (NCT02968472) | The First People's Hospital of Yunnan | 2015-03-01 |
| Cellular Immunotherapy in Treating Patients With High-Risk Acute Lymphoblastic Leukemia (NCT02146924) | City of Hope Medical Center | 2014-10-16 |
| Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations (NCT02883049) | National Cancer Institute (NCI) | 2012-02-29 |